Researchers sought to assess the short-term benefit and risk of ticagrelor with aspirin in patients with acute mild-moderate ischemic stroke or high-risk transient ischemic attack.
AXS-07 is an oral agent that consists of meloxicam, a COX-2 preferential nonsteroidal anti-inflammatory drug, and rizatriptan, a 5-HT1B/1D agonist.
Researchers sought to assess the qualitative effects of COVID-19 on patients with migraine who never tested positive for or been diagnosed with COVID-19.
Presenting at the 2022 AAN Annual Meeting, researchers described the characteristics of patients diagnosed with migraine and benign paroxysmal positional vertigo.
Presenting at the 2022 AAN Annual Meeting, researchers assessed the safety and efficacy of monthly erenumab among adult patients with chronic migraine with Asian ancestry.
Researchers sought to establish whether frequent use of a combined biofeedback-virtual reality device is associated with improvements in chronic migraine, especially in patients refractory to pharmacotherapy.
Presenting at the 2022 AAN Annual Meeting, researchers evaluated acute and persistent headache in patients hospitalized with COVID-19.
In a noninferiority randomized trial, researchers compared the effects of amitriptyline and venlafaxine reducing severity and frequency of migraine attacks.
Adverse childhood experiences (ACEs) are associated with migraine onset in adolescence.
There is a bidirectional association between anxiety and depression and migraine and tension-type headache (TTH).
